vimarsana.com
Home
Live Updates
Dr Li on the Investigation of BDC-1001 in HER2-expressing So
Dr Li on the Investigation of BDC-1001 in HER2-expressing So
Dr Li on the Investigation of BDC-1001 in HER2-expressing Solid Tumors
Bob T. Li, MD, PhD, MPH, discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.
Related Keywords
China ,
Bobt Li ,
,
Bobst International Center ,
Memorial Sloan Kettering Cancer Center ,
Thoracic Liquid Biopsy Program ,